Post Profile






People infected by hepatitis C in Canada have limited access to direct-acting antivirals

(University of Montreal Hospital Research Centre (CRCHUM) ) The new direct-acting antivirals (DAA) are effective in curing the hepatitis C virus infection, a potentially fatal disease that attacks the liver. But they are expensive--approximately $60,000 per patient. A study conducted by researchers at the University of Montreal Hospital Research Centre (CRCHUM), The Kirby Institute, UNSW Australia, and the Canadian Network on Hepatitis C (CanHepC) shows that nearly everywhere in Canada, provinces and territories impose obstacles to the reimbursement of these medications by the public system.
read more

share

Related Posts


New Antiviral Treatment Could Significantly Reduce Global Burden Of Hepatitis C

Health : Medical News Today

Scientists show potential impact of therapy in reducing transmission in UK, Canada and Australia Around 150 million people globally are chronically infected with the hepatitis C virus (HCV) - a major cause of liver disease and the f...

Targeted Hepatitis B Virus Screening Effective in Addressing Infection, Liver Disease Risk

Health : Newswise Medical News

A community-based hepatitis B virus screening effort led by UC Davis researchers found that targeted outreach to Asian American populations can identify groups at high risk for infection and direct them to appropriate follow-up care...

Arrival Of Direct Antiviral Agent Therapy For Hepatitis C Sparks Debate Of Who To Treat First

Health : Medical News Today

For many patients with the hepatitis C virus (HCV), direct antiviral agents (DAA) offer a potential cure for the disease. The Food and Drug Administration (FDA) has recently approved two new DAAs, telaprevir and boceprevir, and with...

People Infected by Hepatitis C in Canada Have Limited Access to Direct-Acting Antivirals

Health : Newswise Medical News

A study conducted by Canadian and Australian researchers shows that nearly everywhere in Canada, the provinces and territories impose obstacles to reimbursement of new direct-acting antivirals (DAA) to treat hepatitis C by because o...

Hepatitis C New Study On Drug Treatment In Vivo And In Vitro

Health : Medical News Today

Hepatitis C virus (HCV) infection affects about 4.1 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) a...

Comments


Copyright © 2016 Regator, LLC